Acton-based Neuroptix Corp. has sold $4.6 million of a planned $9.1 million offering of equity and option or warrant securities, according to a filing with the U.S. Securities and Exchange Commission. The money will be available for general corporate purposes, per the regulatory filing.
The company is developing combined optical scanning devices and diagnostic agents for the early detection of Alzheimer’s disease. Its Sapphire diagnostic platform uses non-invasive quantitative measurements of amyloid aggregates in the eye to examine and measure deposits in specific areas of the lens to detect Alzheimer’s disease. According to the company’s website, the product is only available in the U.S. for investigational purposes.